{"filings":[{"id":442684,"accession_number":"0001437749-26-017049","cik":811641,"company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","form_type":"8-K","filed_at":"2026-05-14T20:09:02+00:00","items":["2.02","9.01"],"status":"ready","headline":"ImmuCell Q1 2026 net income $1.9M, product sales up 28.4% to $10.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $1.9M ($0.21/share) vs $1.4M ($0.16/share) in Q1 2025.","Product sales $10.4M, up 28.4% YoY; gross margin 45.0% vs 41.6%.","Cash position $6.8M at Mar 31, 2026, up from $3.8M; generated $3.4M free cash flow in Q1.","Settled all disputes with former contract manufacturer for net $2M payment to ImmuCell, to fund capacity expansion.","Manufacturing output increased to >450K units/month from ~380K in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":10357295.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":96167469.82666668,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99004,"accession_number":"0001437749-26-015945","cik":811641,"company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"ImmuCell settles Norbrook dispute, to receive $2M payment","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["ImmuCell and Norbrook entered a Settlement Deed on May 8, 2026 resolving all claims from a 2019 Development and Supply Agreement.","Norbrook will pay ImmuCell $2,000,000 under the settlement.","The underlying agreement expired on March 31, 2026.","Settlement deed governed by Northern Ireland law; no admission of liability or wrongdoing.","Confidentiality undertakings included in the agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":96167469.82666668,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99003,"accession_number":"0001437749-26-012182","cik":811641,"company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","form_type":"8-K","filed_at":"2026-04-14T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"ImmuCell appoints two new independent directors; three directors retire effective April 15, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bryan Gathagan, Michael Brigham, and Bobbi Jo Brockmann retire from board effective April 15, 2026.","Gilles Guillemette DVM and Anthony DiMarco Ph.D. elected as new directors effective same date.","Board moves to 7 members with 6 independent directors; CEO remains only non-independent.","New Strategy & Technology Committee formed; Guillemette chairs it; DiMarco serves on it.","Guillemette has 30+ years animal health executive experience; DiMarco 40 years biologics R&D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":96167469.82666668,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99002,"accession_number":"0001437749-26-011757","cik":811641,"company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","form_type":"8-K","filed_at":"2026-04-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ImmuCell reports Q1 2026 preliminary sales up 28.4% to $10.4M; Tri-Shield up 38.5%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total product sales $10.4M vs $8.1M in Q1 2025, a 28.4% increase.","Domestic sales $9.7M (+35.7%); international sales $0.6M (-30.2%).","Tri-Shield First Defense sales $7.9M (+38.5%); Dual-Force & Other $2.5M (+4.4%).","CFO notes prior backorder situation still complicates comparisons but operational progress shown.","Conference call scheduled for May 15, 2026 at 9:00 AM ET."],"consensus_eps_estimate":null,"consensus_eps_actual":0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":10357295.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":96167469.82666668,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114774,"accession_number":"0001437749-26-008842","cik":811641,"company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","form_type":"8-K","filed_at":"2026-03-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ImmuCell appoints Kathy Turner to board, replacing retiring Steven Rosgen","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steven Rosgen resigns from the board effective April 1, 2026, after 8 years of service.","Kathy Turner elected to board effective April 1; will chair Compensation Committee and serve on Audit Committee.","Turner brings 30+ years of animal health experience, including former Elanco board member and IDEXX/Abbott leadership roles."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":96167469.82666668,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114773,"accession_number":"0001437749-26-006912","cik":811641,"company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ImmuCell reports 2025 net operating income $1.6M; net loss narrows to $1.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product sales $27.6M, up 4.3% YoY; gross margin improved to 41.4% from 30%.","Net loss $1.0M ($0.12/share) vs $2.2M ($0.26/share) in 2024.","Net operating income $1.6M vs operating loss $1.6M in 2024.","Non-recurring items: $2.7M Re-Tain write-down, $651K colostrum write-downs, $297K CEO transition costs, $427K insurance proceeds.","Cash $3.8M, no debt draw; net working capital $13M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":96167469.82666668,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114772,"accession_number":"0001437749-26-003514","cik":811641,"company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","form_type":"8-K","filed_at":"2026-02-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Two ImmuCell directors will not seek re-election at 2026 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steven A. Rosgen and Bryan K. Gathagan will not stand for re-election, citing time constraints from full-time roles.","Both directors expressed support for the company's new strategic direction and management.","Nominating Committee is evaluating board composition changes, factoring in these retirements.","Effective at the 2026 Annual Meeting of Shareholders; no replacements named yet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":96167469.82666668,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114771,"accession_number":"0001437749-26-002685","cik":811641,"company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"ImmuCell enters new employment agreements with CFO, SVP; grants stock options","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Fiori base salary $315k, target bonus 50% of base, option for 120k shares at $6.26.","SVP Brockmann base salary $300k, same bonus structure, option for 100k shares.","CEO te Boekhorst gets performance-based option for 110k shares, vests only if 4-quarter net operating income ≥ 300% of FY2025 audited NOI.","Options vest in 3 equal annual installments starting Jan 2027, expire 10 years, subject to change-of-control acceleration.","Effective January 27, 2026; agreements include clawback and severance provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":96167469.82666668,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114770,"accession_number":"0001437749-26-000885","cik":811641,"company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["2.02","2.06","8.01","9.01"],"status":"ready","headline":"ImmuCell reports Q4 sales down 1.6% YoY; records $3.6M impairment, pauses Re-Tain","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total sales $7.6M (-1.6% YoY); domestic sales up 8.7%, international down 52.6%.","FY 2025 total sales $27.6M (+4.3% YoY); Tri-Shield sales $19.9M (+26.5%), Dual-Force $6.9M (-27.4%).","Records $3.6M non-cash impairment: $2.9M Re-Tain PPE, $0.1M other PPE, $0.6M colostrum inventory write-down.","Pausing Re-Tain investment after FDA Incomplete Letter; repurposing $15.5M Re-Tain assets for First Defense.","Tri-Shield sales exceed expectations; expanding sales force by 50% with new U.S. territories and international hire."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":27644174.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":96167469.82666668,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131156,"accession_number":"0001437749-25-038773","cik":811641,"company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["2.06","8.01","9.01"],"status":"ready","headline":"ImmuCell pauses Re-Tain after FDA incomplete letter, shifts focus to First Defense; $2.3M impairment","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA issued Incomplete Letter for Re-Tain NADA on Dec 23 due to contract manufacturer inspection issues; four of five Technical Sections had Complete Letters.","ImmuCell pauses further investment in Re-Tain; will complete studies and seek to license or partner the product.","Non-cash impairment write-down of ~$2.3M on Re-Tain property, plant and equipment in Q4 2025.","First Defense sales force increased by 50%, new U.S. territories created, international senior dairy executive to be hired.","First Defense revenue grew from ~$4.4M to ~$27.8M (TTM Sep 30, 2025) with >13% CAGR over 15 years; targeting $900M global TAM."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":96167469.82666668,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131155,"accession_number":"0001437749-25-034819","cik":811641,"company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ImmuCell Q3 product sales $5.5M (-8% YoY); net loss narrows to $140k; gross margin recovers to 43%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product sales Q3 2025: $5.5M, down 8% YoY; nine-month 2025: $20.0M, up 7% YoY.","Net loss Q3 2025: ($140k) or ($0.02)/share vs ($702k) loss in Q3 2024.","Net income nine-month 2025: $1.8M ($0.20 diluted) vs ($2.7M) loss in prior period.","Gross margin improved to 43% Q3 2025 vs 26% Q3 2024; nine-month 42.6% vs 27.3%.","Adjusted EBITDA Q3: $751k vs $196k; nine-month: $4.4M vs $35k; cash $3.9M, no debt drawn."],"consensus_eps_estimate":null,"consensus_eps_actual":0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":20018175.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":96167469.82666668,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131154,"accession_number":"0001437749-25-033017","cik":811641,"company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["5.02","9.01","2.02"],"status":"ready","headline":"ImmuCell names Olivier te Boekhorst CEO; board expanded to nine directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Olivier te Boekhorst started as President and CEO on Nov 1, 2025, succeeding Michael Brigham.","Board expanded from 7 to 9 directors; te Boekhorst and CFO Timothy Fiori elected as directors.","Michael Brigham remains board member and Special Advisor to CEO until January 2026.","CFO Fiori also appointed Secretary and Treasurer.","Company to host Q3 earnings conference call on Nov 14, 2025 at 9:00 AM ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":96167469.82666668,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131153,"accession_number":"0001437749-25-030631","cik":811641,"company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ImmuCell Q3 sales fall 8% to $5.5M; 9-month sales up 7% to $20M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q3 2025 product sales $5.5M vs $6.0M in Q3 2024, an 8% decrease.","Nine-month 2025 sales $20.0M, up 7% from $18.7M; trailing twelve-month sales $27.8M, up 16%.","Drop attributed to end of distributor restocking that boosted H1 2025; guidance warned of H2 softening.","Re-Tain Investigational Product use started in controlled study with Michigan State; no revenue expected.","Non-Administrative NADA for Re-Tain submitted Jan. 2025; clearance of contract manufacturer inspection remaining hurdle."],"consensus_eps_estimate":null,"consensus_eps_actual":0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":20018175.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":96167469.82666668,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147733,"accession_number":"0001437749-25-030110","cik":811641,"company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","form_type":"8-K","filed_at":"2025-09-30T23:59:59+00:00","items":["1.01","5.02","9.01","2.02"],"status":"ready","headline":"ImmuCell appoints Olivier te Boekhorst as President and CEO effective Nov 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Olivier te Boekhorst, former IDEXX Senior VP and Archimed Operating Partner, named CEO.","Current CEO Michael Brigham to become Special Advisor for at least two months and remain on Board.","Base salary of $450,000, annual bonus up to $400,000, $100,000 signing bonus.","Received inducement stock option for 76,673 shares at $5.90; second grant for up to 85,000 shares.","Options vest over three years; options granted Sep 16, 2025 have 10-year term."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":96167469.82666668,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147732,"accession_number":"0001213900-25-080110","cik":811641,"company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","form_type":"8-K","filed_at":"2025-08-25T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"ImmuCell extends $1M line of credit with Maine Community Bank to Sept 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$1M line of credit extended through September 11, 2026.","Interest on borrowings is variable at the National Prime Rate per annum.","Original line of credit dated March 11, 2020, unchanged except maturity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":96167469.82666668,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147731,"accession_number":"0001213900-25-076633","cik":811641,"company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ImmuCell swings to Q2 profit of $502k on 18% sales growth to $6.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 product sales $6.4M, up 18% YoY; H1 sales $14.5M, up 14%.","Net income $502k ($0.06/diluted) vs loss of ($1.5M) in Q2 2024.","Gross margin improved to 44% from 22%; adjusted EBITDA $1.4M in Q2.","Cash rose to $6.0M from $3.8M at Dec 2024; no line-of-credit draws.","Re-Tain: initiating field feedback, reducing R&D spend, exploring strategic options."],"consensus_eps_estimate":null,"consensus_eps_actual":0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":14512054.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":96167469.82666668,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147730,"accession_number":"0001213900-25-074983","cik":811641,"company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"ImmuCell refinances bank debt with $2.3M loan at 6.5%, extending to 2030","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $2,327,119 loan at 6.5% fixed from Maine Community Bank; pays off prior loans at 7% and 8%.","Prior loans had ~$1.946M balloon payments due in Q3 2026; new loan amortizes through Q3 2030.","Refinancing reduces annual interest expense and removes near-term balloon payment risk.","Loan secured by substantially all assets; failure to pay could accelerate maturity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":96167469.82666668,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147729,"accession_number":"0001213900-25-062192","cik":811641,"company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ImmuCell Q2 2025 preliminary sales up 18% YoY to $6.4M; backlog cleared","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q2 2025 product sales $6.4M, up 18% from $5.5M in Q2 2024.","Twelve-month sales ended June 30, 2025 were $28.3M, up 22% YoY from $23.2M.","Order backlog reduced to under $100k as of June 30, 2025, down from $3.4M on May 6.","Evaluating additional capacity investments to increase production capacity to ~$40M per year.","Conference call scheduled for August 15, 2025 to discuss full Q2 2025 financial results."],"consensus_eps_estimate":null,"consensus_eps_actual":0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":14512054.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":96167469.82666668,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166417,"accession_number":"0001213900-25-057768","cik":811641,"company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ImmuCell CEO Michael Brigham plans retirement by early 2026; board launches succession search","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["President/CEO Michael Brigham (65) intends to retire from full-time work by early 2026; board has started successor search.","Brigham's prior CFO responsibilities transferred to recently hired CFO Timothy C. Fiori.","Goal to identify new CEO candidate by around year-end 2025; Brigham will stay until transition complete.","Brigham to remain on board through term ending June 2026 and beyond, subject to stockholder vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":96167469.82666668,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166416,"accession_number":"0001213900-25-055144","cik":811641,"company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"ImmuCell shareholders reject say-on-pay and stock plan increase at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected; no director received more than 50% withhold.","Say-on-pay advisory resolution failed: 42.66% for, 50.71% against, remainder abstain.","Proposal to increase 2017 Plan shares from 650k to 900k failed: 41.10% for, 6.33% against.","Ratification of Wipfli LLP as auditor passed: 95.93% of votes cast in favor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.15,"market_cap_usd":96167469.82666668,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166415,"accession_number":"0001213900-25-043290","cik":811641,"company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ImmuCell Q1 product sales up 11% to $8.1M, net income $1.4M ($0.16 EPS) vs loss year ago","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 product sales $8.1M (record high), up 11% YoY; 6-month sales $15.8M (+28%).","Net income $1.4M ($0.16 diluted EPS) vs net loss of $438K ($0.06 loss) in Q1 2024.","Gross margin improved to 42% from 32% YoY; adjusted EBITDA $2.3M for Q1.","Cash $4.6M, no draw on $1M line; working capital $12.1M, equity $29M.","Contract manufacturer issues delay Re-Tain; company exploring strategic options for the technology."],"consensus_eps_estimate":null,"consensus_eps_actual":0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":8067174.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.72,"calibrated_materiality_score":0.72,"market_cap_usd":96167469.82666668,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166414,"accession_number":"0001213900-25-029914","cik":811641,"company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","form_type":"8-K","filed_at":"2025-04-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ImmuCell reports record Q1 2025 sales of $8.1M, up 11% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary unaudited product sales for Q1 2025: $8.1M, up 11% from $7.3M in Q1 2024.","All-time quarterly sales record; six-month ($15.8M) and twelve-month ($27.3M) periods also record.","Order backlog reduced to $4.0M as of March 31, 2025, from $4.4M at Dec 31, 2024.","Annualized Q1 sales were approximately 108% of estimated $30M annual capacity.","NADA submission for Re-Tain progressing; critical path remains inspection at contract manufacturer."],"consensus_eps_estimate":null,"consensus_eps_actual":0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":8067174.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":96167469.82666668,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166413,"accession_number":"0001213900-25-029407","cik":811641,"company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"ImmuCell appoints Timothy C. Fiori as CFO effective April 7, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Fiori served 24 years at IDEXX Laboratories, most recently as Senior Director Finance, Commercial Operations.","Annual base salary set at $250,000; eligible for company benefit plans and 2017 Stock Option and Incentive Plan.","Incentive Compensation Agreement provides cash bonuses tied to attainment of specific objectives.","Press release dated April 7, 2025 furnished as Exhibit 99.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":96167469.82666668,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183855,"accession_number":"0001213900-25-017067","cik":811641,"company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ImmuCell Q4 product sales up 52% to $7.8M; net income $515k vs loss year ago","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product sales for Q4 2024 rose 52% to ~$7.8M; full-year sales up 52% to ~$26.5M.","Q4 net income of $515k ($0.06 diluted EPS) vs net loss of $1.14M ($0.15) in Q4 2023.","Gross margin improved to 37% in Q4 2024 from 25% in Q4 2023; EBITDA turned positive at $1.33M.","No contamination events since April 2024; management believes remediation is effective.","Pending FDA clearance for Re-Tain®; NADA submitted Jan 2025 seeking expedited review."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":26493169.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":96167469.82666668,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183854,"accession_number":"0001213900-25-004200","cik":811641,"company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","form_type":"8-K","filed_at":"2025-01-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ImmuCell settles insurance claim for $426,587; total recovery $676,587 from contamination events","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Settlement of $426,587 received for production contamination losses from late 2022 through April 2024.","This amount is in addition to the $250,000 previously recognized in Q3 2023, bringing total claim recovery to $676,587.","The insurance claim was long outstanding; settlement resolves coverage for previously disclosed contamination events.","Company plans to report Q4 and full-year 2024 results on conference call February 26, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":96167469.82666668,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183853,"accession_number":"0001213900-25-002326","cik":811641,"company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ImmuCell reports preliminary Q4 2024 sales of $7.8M, up 52% YoY; full year $26.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q4 2024 product sales $7.8M vs $5.1M in Q4 2023 (+52%); FY2024 sales $26.5M vs $17.5M (+52%).","Annualized Q4 production output ~103% of estimated $30M/year capacity; backlog fell to $4.4M from $9.4M.","Contract manufacturer submitted response to FDA inspection observations; company filed Non-Administrative NADA for Re-Tain® in January.","Conference call to discuss full unaudited results on February 26, 2025 at 9:00 AM ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":96167469.82666668,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200451,"accession_number":"0001213900-24-106933","cik":811641,"company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","form_type":"8-K","filed_at":"2024-12-09T23:59:59+00:00","items":["1.01","5.02","1.02","9.01"],"status":"ready","headline":"ImmuCell VP of Manufacturing to retire July 2025; enters separation agreement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Elizabeth L. Williams moves to part-time effective Dec 7, 2024; retires July 1, 2025.","She will work ≤10 hrs/week transitioning tasks; all prior employment agreements terminated.","Eligible for $100,000 transition incentive if she works through June 30, 2025 and signs affirmation.","Outstanding stock options continue to vest per plan terms until separation date.","During transition she accrues no PTO and loses group health coverage (COBRA available at own cost)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":96167469.82666668,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200450,"accession_number":"0001213900-24-104543","cik":811641,"company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","form_type":"8-K","filed_at":"2024-12-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ImmuCell amends Norbrook agreement; termination March 31, 2026 if FDA approval not received by Feb 28, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Norbrook will complete manufacture of current in-process inventory.","Agreement terminates March 31, 2026, subject to terms.","If FDA approval for Re-Tain not received by Feb 28, 2026, agreement expires and Norbrook invoices Final Balance.","Amendment continues other terms of the Development Services and Commercial Supply Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":96167469.82666668,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200449,"accession_number":"0001213900-24-097449","cik":811641,"company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ImmuCell reports Q3 2024 product sales up 11% to $6M; net loss narrows to $702k","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product sales $6M in Q3 2024 vs $5.4M in Q3 2023 (+11%); 9-month sales $18.7M (+51% YoY).","Net loss $702k ($0.09/sh) vs $940k ($0.12/sh) in Q3 2023; 9-month loss $2.7M vs $4.6M.","Gross margin improved to 26% of sales in Q3 2024 from 23% in Q3 2023.","EBITDA turned positive to ~$119k in Q3 2024 from ($95k) in Q3 2023.","Cash increased to $3.8M from $979K at Dec 31, 2023; no line of credit drawn."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":18742040.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":96167469.82666668,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200448,"accession_number":"0001213900-24-086275","cik":811641,"company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","form_type":"8-K","filed_at":"2024-10-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ImmuCell reports Q3 2024 preliminary sales of $6.0M, up 11% YoY; backlog $7.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2024 total sales $6.0M (+11% YoY); nine-month sales $18.7M (+51% YoY).","Twelve-month sales $23.8M (+46% YoY); production at 77% of ~$30M annual capacity.","Backlog of orders $7.3M; reflects strong demand as distributors replenish stocks.","Plans to submit Re-Tain NADA later this year after contract manufacturer resolves FDA issues.","Conference call on Nov 14, 2024 at 9:00 AM ET to discuss full Q3 results."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":18742040.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":96167469.82666668,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216486,"accession_number":"0001213900-24-081304","cik":811641,"company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","form_type":"8-K","filed_at":"2024-09-24T23:59:59+00:00","items":["1.01","2.03","5.03","9.01"],"status":"ready","headline":"ImmuCell restructures lease payment, deferring $368,743 into monthly installments through July 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Fifth Amendment of Lease with TVP, LLC replaces $368,743 lump sum due Jan 2025 with six $20,000 monthly payments (Jan-Jun 2025) and a $248,743 payment in July 2025.","Leased premises at 175 Industrial Way, Portland, Maine; amendment effective September 20, 2024.","Bylaws amended to update provisions per Delaware law and allow uncertificated shares; administrative changes only."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":96167469.82666668,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216485,"accession_number":"0001213900-24-068243","cik":811641,"company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ImmuCell Q2 product sales up 55% but net loss $1.5M; FDA incomplete letter for Re-Tain","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product sales $5.5M (+55% YoY); six-month sales $12.7M (+82% YoY).","Net loss $1.5M ($0.20/sh) in Q2 2024 vs $1.4M loss ($0.18/sh) in Q2 2023.","Gross margin fell to 22% from 30% due to contamination issues and yield losses.","FDA issued CMC Technical Section Incomplete Letter for Re-Tain; resubmission hinges on contract manufacturer inspection resolution.","Backlog $7.9M as of Aug 6 2024, down from $9.4M at Dec 31 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":12730467.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":96167469.82666668,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216484,"accession_number":"0001213900-24-060121","cik":811641,"company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","form_type":"8-K","filed_at":"2024-07-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ImmuCell reports preliminary Q2 sales of $5.47M, up 55% YoY; H1 sales up 82%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 preliminary sales $5.47M vs $3.53M in Q2 2023, a 55% increase.","Six-month sales $12.73M, up 82% from $6.98M; twelve-month sales $23.22M, up 48%.","Backlog of orders as of June 30, 2024: approx. $8.93M.","Production output at 74% of $30M full capacity in Q2; goal to produce $14M in H2 to reach ~95%.","Still working on FDA approval for Re-Tain; expect fourth CMC submission after manufacturer issues resolved."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":12730467.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":96167469.82666668,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236094,"accession_number":"0001213900-24-052776","cik":811641,"company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"ImmuCell amends lease to defer $488,743 tenant improvement payment over six months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Replaces $488,743 lump-sum rent due July 2024 with $20K/month Jul–Dec 2024 plus $368,743 in Jan 2025.","Additional monthly payments are on top of all other lease amounts; lease must remain current or amendment void.","Fourth Amendment of Lease for Portland, ME facility with TVP, LLC dated June 11, 2024.","Deferral improves short-term cash flow; $368,743 balloon remains in January 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":96167469.82666668,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236093,"accession_number":"0001213900-24-052706","cik":811641,"company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"ImmuCell shareholders elect all 7 directors, approve say-on-pay, ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 7 director nominees elected with 88% or more of votes cast (excluding broker non-votes).","Non-binding advisory resolution on executive compensation passed with 66% of shares voted in favor.","Ratification of Wipfli LLP as independent auditor for 2024 approved with 99.5% of shares voted.","Over 78% of outstanding shares (6,071,108) were represented at the June 13, 2024 annual meeting.","Broker non-votes were 1,649,057 on director elections and say-on-pay; none on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":96167469.82666668,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236092,"accession_number":"0001213900-24-050197","cik":811641,"company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ImmuCell provides Re-Tain® FDA update; NADA submission after contract manufacturer clearance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received FDA Incomplete Letter on CMC Technical Section for Re-Tain®; fourth submission prepared.","ImmuCell's drug substance facility inspection cleared; contract manufacturer responses due by end of June 2024.","Anticipates submitting Non-Administrative NADA with up to 180-day review, possibly shorter.","Targets product expiration dating between Q2 2025 and Q1 2026, subject to FDA approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":96167469.82666668,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236091,"accession_number":"0001213900-24-042926","cik":811641,"company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ImmuCell Q1 2024: Record sales $7.3M (+111% YoY); net loss narrows; FDA delays Re-Tain","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product sales of $7.3M, up 111% YoY from $3.4M; all-time quarterly record.","Net loss improved to $438k ($0.06/sh) vs $2.3M loss ($0.30/sh) a year ago.","Gross margin rose to 32% from 9%, driven by recovery from 2023 contamination events.","Production output annualized to $28.7M (~96% of $30M capacity); backlog $9.1M.","FDA issued Incomplete Letter for Re-Tain CMC; requires contract manufacturer inspection resolution before resubmission."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":7257577.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":96167469.82666668,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236090,"accession_number":"0001213900-24-031647","cik":811641,"company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","form_type":"8-K","filed_at":"2024-04-09T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ImmuCell enters ATM offering agreement for up to $11M common stock with Craig-Hallum","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company entered into ATM offering agreement with Craig-Hallum for up to $11M of common stock.","Craig-Hallum will receive 3.0% commission on gross proceeds from sales.","Company amended FAME loan agreement to remove restrictions on equity issuance.","Offering is under effective shelf registration statement (S-3) filed April 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":96167469.82666668,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236089,"accession_number":"0001213900-24-031589","cik":811641,"company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","form_type":"8-K","filed_at":"2024-04-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ImmuCell reports record Q1 2024 sales of $7.3M, up 111% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total sales for Q1 2024: $7.3M, 111% increase from $3.4M in Q1 2023.","Trailing twelve-month sales ended Mar 31, 2024: $21.3M, up 33% from $16.0M.","Backlog of orders $9.1M at Mar 31, 2024, down from $9.4M Dec 2023 but up from $2.5M Dec 2022.","Company expects FDA response on Re-Tain CMC Technical Section by May 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":7257577.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":96167469.82666668,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}